Trials / Completed
CompletedNCT00682786
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5FU | |
| RADIATION | Radiation | |
| PROCEDURE | Surgery of resectable lesions | |
| DRUG | Irinotecan |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2008-12-01
- Completion
- 2010-08-01
- First posted
- 2008-05-22
- Last updated
- 2017-10-06
- Results posted
- 2014-09-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00682786. Inclusion in this directory is not an endorsement.